Cargando…

Factors affecting post-embolization fever and liver failure after trans-arterial chemo-embolization in a cohort without background infective hepatitis- a prospective analysis

BACKGROUND: Transarterial-chemo-embolization (TACE) is used for palliation of unresectable hepatocellular carcinoma (HCC). We studied the tolerability of TACE in a cohort of patients with NASH and alcoholic cirrhosis related HCC. METHODS: Of 290 patients with HCC (July 2011 - December 2014), 84 unde...

Descripción completa

Detalles Bibliográficos
Autores principales: Siriwardana, Rohan Chaminda, Niriella, Madunil Anuk, Dassanayake, Anuradha Supun, Liyanage, Chandika Anuradha Habarakada, Upasena, Angappulige, Sirigampala, Chandra, de Silva, Hithanadura Janaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4524364/
https://www.ncbi.nlm.nih.gov/pubmed/26239844
http://dx.doi.org/10.1186/s12876-015-0329-8
_version_ 1782384179987611648
author Siriwardana, Rohan Chaminda
Niriella, Madunil Anuk
Dassanayake, Anuradha Supun
Liyanage, Chandika Anuradha Habarakada
Upasena, Angappulige
Sirigampala, Chandra
de Silva, Hithanadura Janaka
author_facet Siriwardana, Rohan Chaminda
Niriella, Madunil Anuk
Dassanayake, Anuradha Supun
Liyanage, Chandika Anuradha Habarakada
Upasena, Angappulige
Sirigampala, Chandra
de Silva, Hithanadura Janaka
author_sort Siriwardana, Rohan Chaminda
collection PubMed
description BACKGROUND: Transarterial-chemo-embolization (TACE) is used for palliation of unresectable hepatocellular carcinoma (HCC). We studied the tolerability of TACE in a cohort of patients with NASH and alcoholic cirrhosis related HCC. METHODS: Of 290 patients with HCC (July 2011 - December 2014), 84 underwent TACE. They were monitored for post-TACE complications: postembolization fever (PEF), nausea and vomiting (NV), abdominal pain, infection, acute hepatic decompensation (AHD) and acute kidney injury (AKI). RESULTS: 84 patients [90.5 % males, 89.2 % cirrhotics, 89.2 % nodular HCC, median age 63 (34–84) years] underwent 111 TACE sessions. All were Child class A [69.4 % sessions (n = 77)] or B; ascites and portal vein invasion was present in 18 (16.2 %) and 15 (13.6 %), respectively. 42 (38.2 %) TACE procedures resulted in complications [PEF 28 (25.2 %), NV 4 (3.6 %), abdominal pain 9 (8.1 %), infection 7 (6.3 %), AHD 13 (11.7 %), AKI 3 (2.7 %)]. There were no immediate post-TACE deaths. On univariate analysis elevated serum bilirubin (p = 0.046) and low serum albumin (p = 0.035) predicted PEF while low serum albumin (p = 0.021) and low platelet counts (p = 0.041) predicted AHD. In the multivariate model, factors with p < 0.200 on univariate analysis and factors derived from the previous literature were considered covariates. Female gender (p = 0.029, OR = 1.412), ascites (p = 0.030, OR = 1.212), elevated serum bilirubin (p = 0.007, OR = 4.357) and large tumour size (p = 0.036, OR = 3.603) were independent risk factors for PEF. Tumour diameter >5 cm (p = 0.049, OR = 2.410) and elevated serum bilirubin (p = 0.036, OR = 1.517) predicted AHD. CONCLUSION: In NASH and alcoholic cirrhosis related HCC patients pre-procedure serum bilirubin, ascites, tumour size and female gender predicted PEF post-TACE. Tumours larger 5 cm with elevated bilirubin predicted AHD post-TACE.
format Online
Article
Text
id pubmed-4524364
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-45243642015-08-05 Factors affecting post-embolization fever and liver failure after trans-arterial chemo-embolization in a cohort without background infective hepatitis- a prospective analysis Siriwardana, Rohan Chaminda Niriella, Madunil Anuk Dassanayake, Anuradha Supun Liyanage, Chandika Anuradha Habarakada Upasena, Angappulige Sirigampala, Chandra de Silva, Hithanadura Janaka BMC Gastroenterol Research Article BACKGROUND: Transarterial-chemo-embolization (TACE) is used for palliation of unresectable hepatocellular carcinoma (HCC). We studied the tolerability of TACE in a cohort of patients with NASH and alcoholic cirrhosis related HCC. METHODS: Of 290 patients with HCC (July 2011 - December 2014), 84 underwent TACE. They were monitored for post-TACE complications: postembolization fever (PEF), nausea and vomiting (NV), abdominal pain, infection, acute hepatic decompensation (AHD) and acute kidney injury (AKI). RESULTS: 84 patients [90.5 % males, 89.2 % cirrhotics, 89.2 % nodular HCC, median age 63 (34–84) years] underwent 111 TACE sessions. All were Child class A [69.4 % sessions (n = 77)] or B; ascites and portal vein invasion was present in 18 (16.2 %) and 15 (13.6 %), respectively. 42 (38.2 %) TACE procedures resulted in complications [PEF 28 (25.2 %), NV 4 (3.6 %), abdominal pain 9 (8.1 %), infection 7 (6.3 %), AHD 13 (11.7 %), AKI 3 (2.7 %)]. There were no immediate post-TACE deaths. On univariate analysis elevated serum bilirubin (p = 0.046) and low serum albumin (p = 0.035) predicted PEF while low serum albumin (p = 0.021) and low platelet counts (p = 0.041) predicted AHD. In the multivariate model, factors with p < 0.200 on univariate analysis and factors derived from the previous literature were considered covariates. Female gender (p = 0.029, OR = 1.412), ascites (p = 0.030, OR = 1.212), elevated serum bilirubin (p = 0.007, OR = 4.357) and large tumour size (p = 0.036, OR = 3.603) were independent risk factors for PEF. Tumour diameter >5 cm (p = 0.049, OR = 2.410) and elevated serum bilirubin (p = 0.036, OR = 1.517) predicted AHD. CONCLUSION: In NASH and alcoholic cirrhosis related HCC patients pre-procedure serum bilirubin, ascites, tumour size and female gender predicted PEF post-TACE. Tumours larger 5 cm with elevated bilirubin predicted AHD post-TACE. BioMed Central 2015-08-04 /pmc/articles/PMC4524364/ /pubmed/26239844 http://dx.doi.org/10.1186/s12876-015-0329-8 Text en © Siriwardana et al. 2015 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Siriwardana, Rohan Chaminda
Niriella, Madunil Anuk
Dassanayake, Anuradha Supun
Liyanage, Chandika Anuradha Habarakada
Upasena, Angappulige
Sirigampala, Chandra
de Silva, Hithanadura Janaka
Factors affecting post-embolization fever and liver failure after trans-arterial chemo-embolization in a cohort without background infective hepatitis- a prospective analysis
title Factors affecting post-embolization fever and liver failure after trans-arterial chemo-embolization in a cohort without background infective hepatitis- a prospective analysis
title_full Factors affecting post-embolization fever and liver failure after trans-arterial chemo-embolization in a cohort without background infective hepatitis- a prospective analysis
title_fullStr Factors affecting post-embolization fever and liver failure after trans-arterial chemo-embolization in a cohort without background infective hepatitis- a prospective analysis
title_full_unstemmed Factors affecting post-embolization fever and liver failure after trans-arterial chemo-embolization in a cohort without background infective hepatitis- a prospective analysis
title_short Factors affecting post-embolization fever and liver failure after trans-arterial chemo-embolization in a cohort without background infective hepatitis- a prospective analysis
title_sort factors affecting post-embolization fever and liver failure after trans-arterial chemo-embolization in a cohort without background infective hepatitis- a prospective analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4524364/
https://www.ncbi.nlm.nih.gov/pubmed/26239844
http://dx.doi.org/10.1186/s12876-015-0329-8
work_keys_str_mv AT siriwardanarohanchaminda factorsaffectingpostembolizationfeverandliverfailureaftertransarterialchemoembolizationinacohortwithoutbackgroundinfectivehepatitisaprospectiveanalysis
AT niriellamadunilanuk factorsaffectingpostembolizationfeverandliverfailureaftertransarterialchemoembolizationinacohortwithoutbackgroundinfectivehepatitisaprospectiveanalysis
AT dassanayakeanuradhasupun factorsaffectingpostembolizationfeverandliverfailureaftertransarterialchemoembolizationinacohortwithoutbackgroundinfectivehepatitisaprospectiveanalysis
AT liyanagechandikaanuradhahabarakada factorsaffectingpostembolizationfeverandliverfailureaftertransarterialchemoembolizationinacohortwithoutbackgroundinfectivehepatitisaprospectiveanalysis
AT upasenaangappulige factorsaffectingpostembolizationfeverandliverfailureaftertransarterialchemoembolizationinacohortwithoutbackgroundinfectivehepatitisaprospectiveanalysis
AT sirigampalachandra factorsaffectingpostembolizationfeverandliverfailureaftertransarterialchemoembolizationinacohortwithoutbackgroundinfectivehepatitisaprospectiveanalysis
AT desilvahithanadurajanaka factorsaffectingpostembolizationfeverandliverfailureaftertransarterialchemoembolizationinacohortwithoutbackgroundinfectivehepatitisaprospectiveanalysis